The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure

What Was Tested

Researchers studied Ghrelin in the context of low blood pressure and orthostatic hypotension in this clinical trial publication.

The aim of this study was to evaluate the effect of endogenously released glucose, insulin, glucagon-like peptide 1 (GLP-1), ghrelin on CO, HR, stroke volume (SV), and blood pressure.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Eleven healthy men and twelve healthy women ((mean ± SEM) aged: 26 ± 0.2 y; body mass index: 21.8 ± 0.1 kg/m(2))) were included in this study.

How the Study Was Run

The CO, HR, SV, systolic and diastolic blood pressure, antral area, gastric emptying rate, and glucose, insulin, GLP-1 and ghrelin levels were measured.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Blood Pressure, Cardiac Output, Diastole, Eating, Echocardiography, Doppler and Fasting.

What This Means in Plain Language

This is a clinical trial of Ghrelin in people with low blood pressure and orthostatic hypotension.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Cardiovascular ultrasound), a journal based in England.

More context: the Ghrelin compound page, Low blood pressure and orthostatic hypotension research.